Skip to Main Content

Blueprint Medicines will receive $25 million to collaborate with the French drug maker Ipsen on a potential medical treatment that the Cambridge, Mass., biotech has developed for an ultra-rare genetic disease.

The licensing deal marks the fourth collaboration between Blueprint — founded in 2008 — and another major drug maker in less than five years.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!